CGEM ▼ -0.1% - Cullinan Therapeutics, Inc.
$CGEM - Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
27-OCT-2026 07:00 AM ET
Share this post
More filings for $CGEM
CGEM ▼ -8.8% - Cullinan Therapeutics, Inc.Nov 12, 2026CGEM ▲ +6.1% - Cullinan Therapeutics, Inc.Nov 10, 2026CGEM - Cullinan Therapeutics, Inc. - SEC Filing Update (10-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 10, 2026CGEM ▲ +0.4% - Cullinan Therapeutics, Inc.Nov 9, 2026CGEM ▲ +5.0% - Cullinan Therapeutics, Inc.Nov 8, 2026CGEM ▲ +0.6% - Cullinan Therapeutics, Inc.Nov 4, 2026
View full $CGEM filing history →💬 Comments
Loading comments…
Leave a comment
